Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Vbi Vaccines Inc CS (NQ: VBIV )

2.860 USD -0.080 (-2.72%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 5, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,726,265
Open 2.980
Bid (Size) 2.900 (34)
Ask (Size) 3.000 (50)
Prev. Close 2.940
Today's Range 2.850 - 3.039
52wk Range 1.180 - 6.930
Shares Outstanding 254,004,515
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Accurate Diagnostic Solutions Remain Vital to Overcoming the Pandemic
FinancialBuzz.com News Commentary 
From PR Newswire
VBI Vaccines Announces Multiple Presentations at the Canadian Liver Meeting 2021
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that two abstracts highlighting... 
From Business Wire News Releases

Performance

YTD
-2.39%
-2.39%
1 Month
-7.14%
-7.14%
3 Month
-22.91%
-22.91%
6 Month
+13.04%
+13.04%
1 Year
+130.65%
+130.65%

More News

Read More
Brii Biosciences, Vir Biotechnology and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B
From GlobeNewswire News Releases
VBI Vaccines Announces Publication of Preclinical and Challenge Study Data of its eVLP Vaccine Candidate Against COVID-19 (VBI-2902)
From Business Wire News Releases
VBI Vaccines to Participate in National Securities Corporation’s Biotech Investor Summit
From Business Wire News Releases
VBI Vaccines Announces Presentation at the 2021 Annual Conference on Vaccinology Research
From Business Wire News Releases
Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B
From Business Wire News Releases
VBI Vaccines Announces Phase 1b/2a Data and Progress of Hepatitis B Immunotherapeutic Candidate
From Business Wire News Releases
VBI Vaccines to Present at Oppenheimer 31st Annual Healthcare Conference
From Business Wire News Releases
Analysts See 63% Upside For XBI
Tags ETFs
From ETF Channel
CEPI and VBI Vaccines Collaborate to Advance Vaccine Candidates Against COVID-19 Variants
From Business Wire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.